Could this be the case of a blown-up long-term opportunity? VBI Vaccines Inc. (VBIV)

As of right now, VBI Vaccines Inc. [VBIV] is trading at $0.64, up 7.02%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VBIV shares have gain 11.67% over the last week, with a monthly amount glided 49.64%, and seem to be holding up well over a long-time horizon.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


On 8, December 2022, VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults. In a post published today on Yahoo Finance, VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Health Canada has approved PreHevbrio™ [3-antigen Hepatitis B Vaccine (Recombinant)] for active immunization against infection caused by all known subtypes of hepatitis B (HBV) virus in adults 18 years of age and older. It can be expected that hepatitis D will also be prevented by immunization with PreHevbrio as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.

From an analyst’s perspective:

VBI Vaccines Inc. [NASDAQ: VBIV] stock has seen the most recent analyst activity on November 11, 2022, when Raymond James downgraded its rating to a Outperform and also revised its price target to $2 from $5. On February 25, 2021, Jefferies initiated with a Buy rating and assigned a price target of $7 on the stock. Raymond James upgraded its rating to a Strong Buy and increased its price target to $9 on August 27, 2020. Oppenheimer initiated its recommendation with a Outperform and recommended $9 as its price target on January 16, 2019. Canaccord Genuity started tracking with a Buy rating for this stock on November 01, 2017, and assigned it a price target of $10. In a note dated October 10, 2016, Laidlaw initiated an Buy rating and iterated a target price of $6 on this stock.

Through the last year, VBI Vaccines Inc.’s stock price ranged from $0.36 to $1.86. Currently, Wall Street analysts expect the stock to reach $4.00 within the next 12 months. VBI Vaccines Inc. [NASDAQ: VBIV] shares were valued at $0.64 at the most recent close of the market. An investor can expect a potential return of 525.0% based on the average VBIV price forecast.

Analyzing the VBIV fundamentals

For VBI Vaccines Inc., (VBIV), the latest quarter sales were 317.0 million, which represents an 200.00% increase. Gross Margin for this corporation currently stands at -1897.62% with Operating Margin at -10781.62%, Pretax Margin comes in at -11054.36%, and Net Margin reading is -11054.36%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5848 points at the first support level, and at 0.5275 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6947, and for the 2nd resistance point, it is at 0.7473.

VBI Vaccines Inc. [VBIV] reported earnings per share of -$0.18 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.07/share, meaning a difference of -$0.11 and a surprise factor of -157.10%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.08 per share as compared to estimates of -$0.08 per share, a difference of $0 representing a surprise of 0.00%.

Ratios To Look Out For

It is important to note that VBI Vaccines Inc. [NASDAQ:VBIV] has a current ratio of 2.80. Also, the Quick Ratio is 3.92, while the Cash Ratio stands at 3.73. Considering the valuation of this stock, the price to sales ratio is 945.45, the price to book ratio is 4.20.